Press Releases

Date Title and Summary  
Toggle Summary Geron Corporation Reports First Quarter 2018 Financial Results
Annual Stockholders Meeting to be Held on May 15, 2018 MENLO PARK, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the first quarter ended March 31, 2018 . First Quarter 2018 Results For the first quarter of 2018, the company reported
Toggle Summary Geron 2018 Annual Meeting of Stockholders to be Held on May 15
First Quarter 2018 Financial Results to be Announced on May 10 MENLO PARK, Calif. , April 17, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will hold its 2018 Annual Meeting of Stockholders, on Tuesday, May 15, 2018 , at 4:00 p.m. PDT . Geron’s stockholders are invited to attend the
Toggle Summary Geron to Present at the Needham Healthcare Conference
MENLO PARK, Calif. , March 21, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett , M.D., President and Chief Executive Officer, is scheduled to present at the 17th Annual Needham Healthcare Conference in New York at 4:00 p.m.
Toggle Summary Geron Corporation Reports Fourth Quarter and Annual 2017 Financial Results and Recent Events
Conference Call Scheduled for 8:30 a.m. ET on Monday, March 19 MENLO PARK, Calif. , March 16, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the fourth quarter and year ended December 31, 2017 and recent events.
Toggle Summary Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2017 Financial Results
MENLO PARK, Calif. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the fourth quarter and year ended December 31, 2017 , on Friday, March 16, 2018 , after the market close. Geron’s management will also host a conference call for analysts
Toggle Summary Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes (MDS) Presented Analyst and Investor Meeting and Webcast at 8:30 a.m. ET on December 19, 2017 MENLO PARK, Calif. , Dec. 12, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced four presentations related
Toggle Summary Geron to Host Analyst and Investor Meeting and Webcast on December 19, 2017
Management to be joined by external guest speaker to review imetelstat data from IMerge to be presented at the 59th American Society of Hematology Annual Meeting and Exposition MENLO PARK, Calif. , Dec. 06, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the company’s
Toggle Summary Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes
MENLO PARK, Calif. , Nov. 20, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the first patient has been dosed in the expanded Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in transfusion dependent patients with Low or Intermediate-1 risk
Toggle Summary Geron Announces November Investor Conference Presentation Webcasts
MENLO PARK, Calif. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett , M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2017 Healthcare Conference in New York at 4:15 p.m.
Toggle Summary Geron Corporation Reports Third Quarter 2017 Financial Results
MENLO PARK, Calif. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and nine months ended September 30, 2017 . For the third quarter of 2017, the company reported a net loss of $6.9 million , or $0.04 per share, compared to $3.6